Trevi Therapeutics Inc
TRVIHealthcare|Biotechnology|USA
$17.84
-0.56 (-3.02%)
Tangible Book
$1.34
Earnings Power
$1.16
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07671911 Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets | Idiopathic Pulmonary Fibrosis | P3 | Recruiting | 306 | RCT, Double-blind | NAL ER, Placebo |
| NCT07671924 The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | Refractory Chronic Cough | P2 | Recruiting | 100 | RCT, Double-blind | NAL ER, Placebo |
| NCT07487740 A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants | Healthy Participants | P1 | Recruiting | 60 | RCT, Open-label | NAL ER |
| NCT07036029 NAL ER IPF Respiratory Function and Safety Study | Idiopathic Pulmonary Fibrosis | P1 | Recruiting | 10 | Open-label | NAL ER, Placebo |
| NCT03497975 PRISM Study-Pruritus Relief Through Itch Scratch Modulation | Prurigo Nodularis | P2P3 | Completed | 353 | RCT, Double-blind | Nalbuphine ER Tablets, Placebo Tablets |
| NCT02174432 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis | Prurigo Nodularis, Nodularis Prurigo | P2P3 | Completed | 36 | Open-label | nalbuphine HCl ER |
| NCT02174419 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis | Prurigo Nodularis, Nodularis Prurigo | P2P3 | Completed | 62 | RCT, Double-blind | nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID |
| NCT02143973 Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus | Uremic Pruritus, Pruritus | P2P3 | Completed | 167 | Open-label | nalbuphine HCl ER |
| NCT02143648 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus | Uremic Pruritus, Pruritus | P2P3 | Completed | 373 | RCT, Double-blind | nalbuphine HCl ER tablets 60 mg BID, nalbuphine HCl ER tablets 120mg BID, Placebo tablets BID |
| NCT05962151 Refractory Chronic Cough Improvement Via NAL ER (RIVER) | Refractory Chronic Cough | P2 | Completed | 66 | RCT, Double-blind | NAL ER, Placebo |
| NCT04030026 A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | Idiopathic Pulmonary Fibrosis | P2 | Completed | 42 | RCT, Double-blind | NAL ER, Placebo |
| NCT05964335 Cough Reduction in IPF With Nalbuphine ER | Idiopathic Pulmonary Fibrosis | P2 | Completed | 165 | RCT, Double-blind | NAL ER, Placebo, NAL ER, NAL ER |
| NCT04018664 Oral Abuse Potential Study of Nalbuphine | Nalbuphine, Opioid Abuse | P1 | Completed | 56 | Double-blind | Nalbuphine HCl solution, Placebo solution |
| NCT02373215 Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus | Uremic Pruritus | P1 | Completed | 22 | Open-label | Nalbuphine HCL ER |
| NCT07015398 A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants | Healthy Participants | P1 | Completed | 132 | Open-label | NAL ER, Pirfenidone, Nintedanib |
| NCT04020016 Study of Nalbuphine ER in Participants With Hepatic Impairment | Hepatic Impairment | P1 | Completed | 28 | Open-label | Nalbuphine ER |
| NCT03395717 Stroke Rehabilitation With Exoskeleton-assisted Gait. | Severe Stroke, Acute Stroke | N/A | Completed | 162 | RCT, Single-blind | — |